バイオバンク市場：タイプ、コンポーネント、サンプルタイプ、用途、エンドユーザー、所有者別-2025～2030年世界予測

バイオバンク市場の2024年の市場規模は1,154億3,000万米ドルで、2025年には1,305億6,000万米ドルに成長し、CAGRは13.49%、2030年には2,467億2,000万米ドルに達すると予測されています。

バイオバンクは、生物学的サンプルと関連データの重要な保管庫として台頭し、研究、診断、個別化医療における画期的な進歩を後押ししています。急速に進化する今日の科学環境において、これらの施設は臨床研究やトランスレーショナルリサーチをサポートするイノベーションの中核となっています。過去10年間、技術の進歩とゲノムと分子基盤の理解の深まりとが相まって、バイオバンクは戦略的資産として位置づけられてきました。この進化は、保管、サンプル分析、データ管理の改善を促し、科学的知見の信頼性と再現性を高めています。バイオバンクの広範な役割は、創薬を加速させるだけでなく、患者に特化した治療にも大きく貢献しています。学術界、バイオテクノロジー、医療の利害関係者は、倫理的、規制的、運用上の課題に取り組みながら、新たな可能性を解き放つために協力関係を強めています。市場が統合されたデジタルプラットフォーム、堅牢なインフラ、先進的分析ツールへとシフトする中、バイオバンクの状況は変革的な成長を遂げようとしています。この採用では、歴史的なマイルストーンと新たな動向の両方を認識しながら、市場力学、セグメンテーション戦略、競争が激化する場での効果的な意思決定をサポートする戦略的考察を詳細に解説します。

情勢の変化：新たな動向と破壊的勢力

バイオバンクのエコシステムの進化は、先駆的なアプローチへの扉を開くと同時に、従来の手法を見直す変革的なシフトによって推進されています。リアルタイムモニタリングシステム、自動サンプル処理、データ分析などの技術的進歩は、収集と管理の実践を再定義しつつあります。デジタル革命の中で、プラットフォームは相互運用性とユーザー中心主義を強め、サンプル採取から分析までのデータの流れを迅速かつ安全なものにしつつあります。規制改革と進化する倫理的配慮も市場を再形成しており、研究機関はより透明で厳格な運営フレームワークを採用するよう求められています。同時に、ゲノム研究と個別化医療構想への投資の増加は、学界、病院、商業ベンチャーが現在と将来の需要に合わせて戦略を再調整する中で、こうしたシフトをさらに刺激しています。さらに、バイオバンキングのためのインフラ開発に世界的に焦点が当てられ、民間部門と公的部門の協力が促進されています。このような環境は、迅速な適応と戦略的再編成によって特徴付けられ、市場関係者が従来の課題を克服し、新たな機会を活用することを可能にしています。その結果、産業水準が向上するだけでなく、世界中のバイオバンキング産業において、前例のない成長と共同革新への道筋が生まれつつあります。

主要セグメントに関する洞察多角的な包括的分析

バイオバンク市場は、複雑でありながら洞察に満ちたセグメンテーションによって特徴付けられ、的を絞った戦略と投資を促進しています。この市場の構造はまず、疾患指向モデル、ゲノムベースのアプローチ、集団ベースのコレクション、ますます関連性が高まっているバーチャルバイオバンクプラットフォームに焦点を当てた研究など、タイプによる観点から観察されます。さらに、消耗品、機器、サービスを通じて市場が調査されるため、コンポーネント別セグメンテーションが重要な役割を果たします。具体的には、機器のセグメンテーションでは、アラームやモニタリングシステム、インキュベーターや遠心分離機、温度制御システムなどのセグメントを掘り下げます。サービス面では、データ管理、サンプル分析、保管・処理、トランスポストなどの主要な業務要素が批判的に評価されます。サンプルタイプを細分化することで、血液、細胞株、核酸、組織がそれぞれ異なる分析・運用パラメータを持つことになります。また、バイオバンキングの用途は臨床診断、個別化医療、研究、治療に区分され、治療領域はさらに医薬品開発と遺伝子編集ベンチャーに区分されます。市場セグメンテーションはまた、学術機関、バイオテクノロジー企業、病院、製薬会社などのエンドユーザー区分に基づいて投資決定を行っています。情勢はさらに学術、商業、政府のバイオバンクに細分化されます。このような多角的なセグメンテーションにより、多様なニーズとイノベーションの軌跡を深く掘り下げることができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • パーソナライズ医療とゲノミクスの需要の高まり
    • 精密医療への取り組みの急速な拡大
    • バイオバンキングインフラ開発への投資増加
  • 抑制要因
    • バイオバンキングの開発と国際的な展開に関する厳格な規制遵守
  • 機会
    • バイオバンキングのプロセスとデータ処理の効率を高める技術の進歩
    • バイオバンクのビッグデータ分析を活用して、パーソナライズされた医療成果を向上させる
  • 課題
    • バイオバンクにおけるデータのプライバシーとセキュリティの問題
• 市場セグメンテーション分析
  • タイプ：疾患の進行と予防戦略に関する縦断的研究を促進するための集団ベースのバイオバンクへの関心の高まり
  • 用途：生物学的サンプルの保存とアクセスのための臨床診断におけるバイオバンクの適用範囲の拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 バイオバンク市場：タイプ別

• イントロダクション
• 病気志向
• ゲノムベース
• 人口ベース
• バーチャル

第7章 バイオバンク市場：コンポーネント別

• イントロダクション
• 消耗品
• 装置
  • 警報とモニタリングシステム
  • インキュベーターと遠心分離機
  • 温度制御システム
• サービス
  • データ管理
  • サンプル分析
  • 保管と処理
  • 輸送

第8章 バイオバンク市場：サンプルタイプ別

• イントロダクション
• 血液製剤
• 細胞株
• 核酸
• 組織

第9章 バイオバンク市場：用途別

• イントロダクション
• 臨床診断
• パーソナライズ医療
• 研究
• 治療
  • 医薬品開発
  • 遺伝子編集

第10章 バイオバンク市場：エンドユーザー別

• イントロダクション
• 学術機関
• バイオテクノロジー企業
• 病院
• 製薬会社

第11章 バイオバンク市場：所有者別

• イントロダクション
• 学術バイオバンク
• 商業バイオバンク
• 政府バイオバンク

第12章 南北アメリカのバイオバンク市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋のバイオバンク市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカのバイオバンク市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析、2024年
• FPNVポジショニングマトリックス、2024年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Acorn Biolabs, Inc.
• AMS BIoTechnology（Europe）Limited
• Artizan Biosciences, Inc.
• ASKION GmbH
• Avantor, Inc.
• Bay Biosciences LLC
• Beckman Coulter, Inc. by Danaher Corporation
• Becton, Dickinson and Company
• BioIVT LLC
• BioKryo by L'AIR LIQUIDE S.A.
• BioLife Solutions Inc.
• BocaBio
• Charles River Laboratories International, Inc.
• Cryoport Systems, LLC
• CTIBIoTech
• Cureline, Inc.
• Firalis Group
• Greiner AG
• Hamilton Company
• LVL Technologies GmbH & Co. KG
• Merck KGaA
• Micronic Holding B.V.
• ProteoGenex, Inc.
• Provia Laboratories, LLC
• Qiagen N.V.
• Shanghai Outdo BIoTech Co. Ltd
• Taylor-Wharton
• Tecan Trading AG
• Thermo Fisher Scientific Inc.
• UK Biobank Limited

LIST OF FIGURES

• FIGURE 1. BIOBANKS MARKET MULTI-CURRENCY
• FIGURE 2. BIOBANKS MARKET MULTI-LANGUAGE
• FIGURE 3. BIOBANKS MARKET RESEARCH PROCESS
• FIGURE 4. BIOBANKS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL BIOBANKS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL BIOBANKS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL BIOBANKS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BIOBANKS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL BIOBANKS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BIOBANKS MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL BIOBANKS MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL BIOBANKS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL BIOBANKS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL BIOBANKS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL BIOBANKS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL BIOBANKS MARKET SIZE, BY OWNERSHIP, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL BIOBANKS MARKET SIZE, BY OWNERSHIP, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS BIOBANKS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. AMERICAS BIOBANKS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES BIOBANKS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 23. UNITED STATES BIOBANKS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC BIOBANKS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC BIOBANKS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BIOBANKS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA BIOBANKS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. BIOBANKS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 29. BIOBANKS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. BIOBANKS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL BIOBANKS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BIOBANKS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOBANKS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BIOBANKS MARKET DYNAMICS
• TABLE 7. GLOBAL BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BIOBANKS MARKET SIZE, BY DISEASE-ORIENTED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOBANKS MARKET SIZE, BY GENOMIC-BASED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BIOBANKS MARKET SIZE, BY POPULATION-BASED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOBANKS MARKET SIZE, BY VIRTUAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOBANKS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BIOBANKS MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOBANKS MARKET SIZE, BY ALARMS & MONITORING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BIOBANKS MARKET SIZE, BY INCUBATORS & CENTRIFUGES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOBANKS MARKET SIZE, BY TEMPERATURE CONTROL SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOBANKS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BIOBANKS MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BIOBANKS MARKET SIZE, BY SAMPLE ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BIOBANKS MARKET SIZE, BY STORAGE & PROCESSING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BIOBANKS MARKET SIZE, BY TRANSPOST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BIOBANKS MARKET SIZE, BY BLOOD DERIVATIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BIOBANKS MARKET SIZE, BY CELL LINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BIOBANKS MARKET SIZE, BY NUCLEIC ACID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL BIOBANKS MARKET SIZE, BY TISSUES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL BIOBANKS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL BIOBANKS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL BIOBANKS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL BIOBANKS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL BIOBANKS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL BIOBANKS MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL BIOBANKS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL BIOBANKS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL BIOBANKS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL BIOBANKS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL BIOBANKS MARKET SIZE, BY ACADEMIC BIOBANKS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL BIOBANKS MARKET SIZE, BY COMMERCIAL BIOBANKS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL BIOBANKS MARKET SIZE, BY GOVERNMENT BIOBANKS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS BIOBANKS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 75. CANADA BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. CANADA BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 77. CANADA BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 78. CANADA BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 79. CANADA BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 80. CANADA BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. CANADA BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 82. CANADA BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 83. CANADA BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 84. MEXICO BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. MEXICO BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 86. MEXICO BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 93. UNITED STATES BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. UNITED STATES BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 95. UNITED STATES BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 96. UNITED STATES BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES BIOBANKS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ASIA-PACIFIC BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 105. ASIA-PACIFIC BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 106. ASIA-PACIFIC BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC BIOBANKS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 113. AUSTRALIA BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. AUSTRALIA BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 115. AUSTRALIA BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 116. AUSTRALIA BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 117. AUSTRALIA BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. AUSTRALIA BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 120. AUSTRALIA BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 122. CHINA BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. CHINA BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 124. CHINA BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 125. CHINA BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 126. CHINA BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. CHINA BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. CHINA BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 129. CHINA BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. CHINA BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 131. INDIA BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. INDIA BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 133. INDIA BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 134. INDIA BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 135. INDIA BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 136. INDIA BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. INDIA BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 138. INDIA BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. INDIA BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 140. INDONESIA BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. INDONESIA BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 142. INDONESIA BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 143. INDONESIA BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 144. INDONESIA BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 145. INDONESIA BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. INDONESIA BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 147. INDONESIA BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 148. INDONESIA BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 149. JAPAN BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. JAPAN BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 151. JAPAN BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 152. JAPAN BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 153. JAPAN BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 154. JAPAN BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. JAPAN BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 156. JAPAN BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 157. JAPAN BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 158. MALAYSIA BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. MALAYSIA BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 160. MALAYSIA BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 161. MALAYSIA BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 162. MALAYSIA BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 163. MALAYSIA BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. MALAYSIA BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 165. MALAYSIA BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. MALAYSIA BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 167. PHILIPPINES BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. PHILIPPINES BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 169. PHILIPPINES BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 170. PHILIPPINES BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 171. PHILIPPINES BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 172. PHILIPPINES BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. PHILIPPINES BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 174. PHILIPPINES BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. PHILIPPINES BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 176. SINGAPORE BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SINGAPORE BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 178. SINGAPORE BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 179. SINGAPORE BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 180. SINGAPORE BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 181. SINGAPORE BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. SINGAPORE BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 183. SINGAPORE BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 184. SINGAPORE BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 185. SOUTH KOREA BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. SOUTH KOREA BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 187. SOUTH KOREA BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 188. SOUTH KOREA BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 189. SOUTH KOREA BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 190. SOUTH KOREA BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. SOUTH KOREA BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 192. SOUTH KOREA BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 193. SOUTH KOREA BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 194. TAIWAN BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 195. TAIWAN BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 196. TAIWAN BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 197. TAIWAN BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 198. TAIWAN BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 199. TAIWAN BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. TAIWAN BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 201. TAIWAN BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 202. TAIWAN BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 203. THAILAND BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 204. THAILAND BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 205. THAILAND BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 206. THAILAND BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 207. THAILAND BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 208. THAILAND BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 209. THAILAND BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 210. THAILAND BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 211. THAILAND BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 212. VIETNAM BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 213. VIETNAM BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 214. VIETNAM BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 215. VIETNAM BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 216. VIETNAM BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 217. VIETNAM BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 218. VIETNAM BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 219. VIETNAM BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 220. VIETNAM BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 227. EUROPE, MIDDLE EAST & AFRICA BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 228. EUROPE, MIDDLE EAST & AFRICA BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 229. EUROPE, MIDDLE EAST & AFRICA BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 230. EUROPE, MIDDLE EAST & AFRICA BIOBANKS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 231. DENMARK BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 232. DENMARK BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 233. DENMARK BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 234. DENMARK BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 235. DENMARK BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 236. DENMARK BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 237. DENMARK BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 238. DENMARK BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 239. DENMARK BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 240. EGYPT BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 241. EGYPT BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 242. EGYPT BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 243. EGYPT BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 244. EGYPT BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 245. EGYPT BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 246. EGYPT BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 247. EGYPT BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 248. EGYPT BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 249. FINLAND BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 250. FINLAND BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 251. FINLAND BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 252. FINLAND BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 253. FINLAND BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 254. FINLAND BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 255. FINLAND BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 256. FINLAND BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 257. FINLAND BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 258. FRANCE BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 259. FRANCE BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 260. FRANCE BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 261. FRANCE BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 262. FRANCE BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 263. FRANCE BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 264. FRANCE BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 265. FRANCE BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 266. FRANCE BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 267. GERMANY BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 268. GERMANY BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 269. GERMANY BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 270. GERMANY BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 271. GERMANY BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 272. GERMANY BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 273. GERMANY BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 274. GERMANY BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 275. GERMANY BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 276. ISRAEL BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 277. ISRAEL BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 278. ISRAEL BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 279. ISRAEL BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 280. ISRAEL BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 281. ISRAEL BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 282. ISRAEL BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 283. ISRAEL BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 284. ISRAEL BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 285. ITALY BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 286. ITALY BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 287. ITALY BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 288. ITALY BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 289. ITALY BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 290. ITALY BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 291. ITALY BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 292. ITALY BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 293. ITALY BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 294. NETHERLANDS BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 295. NETHERLANDS BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 296. NETHERLANDS BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 297. NETHERLANDS BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 298. NETHERLANDS BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 299. NETHERLANDS BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 300. NETHERLANDS BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 301. NETHERLANDS BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 302. NETHERLANDS BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 303. NIGERIA BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 304. NIGERIA BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 305. NIGERIA BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 306. NIGERIA BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 307. NIGERIA BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 308. NIGERIA BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 309. NIGERIA BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 310. NIGERIA BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 311. NIGERIA BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 312. NORWAY BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 313. NORWAY BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 314. NORWAY BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 315. NORWAY BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 316. NORWAY BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 317. NORWAY BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 318. NORWAY BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 319. NORWAY BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 320. NORWAY BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 321. POLAND BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 322. POLAND BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 323. POLAND BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 324. POLAND BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 325. POLAND BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 326. POLAND BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 327. POLAND BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 328. POLAND BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 329. POLAND BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 330. QATAR BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 331. QATAR BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 332. QATAR BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 333. QATAR BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 334. QATAR BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 335. QATAR BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 336. QATAR BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 337. QATAR BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 338. QATAR BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 339. RUSSIA BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 340. RUSSIA BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 341. RUSSIA BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 342. RUSSIA BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 343. RUSSIA BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 344. RUSSIA BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 345. RUSSIA BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 346. RUSSIA BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 347. RUSSIA BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 348. SAUDI ARABIA BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 349. SAUDI ARABIA BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 350. SAUDI ARABIA BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 351. SAUDI ARABIA BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 352. SAUDI ARABIA BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 353. SAUDI ARABIA BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 354. SAUDI ARABIA BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 355. SAUDI ARABIA BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 356. SAUDI ARABIA BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 357. SOUTH AFRICA BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 358. SOUTH AFRICA BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 359. SOUTH AFRICA BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 360. SOUTH AFRICA BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 361. SOUTH AFRICA BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 362. SOUTH AFRICA BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 363. SOUTH AFRICA BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 364. SOUTH AFRICA BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 365. SOUTH AFRICA BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 366. SPAIN BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 367. SPAIN BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 368. SPAIN BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 369. SPAIN BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 370. SPAIN BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 371. SPAIN BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 372. SPAIN BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 373. SPAIN BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 374. SPAIN BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 375. SWEDEN BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 376. SWEDEN BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 377. SWEDEN BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 378. SWEDEN BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 379. SWEDEN BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 380. SWEDEN BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 381. SWEDEN BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 382. SWEDEN BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 383. SWEDEN BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 384. SWITZERLAND BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 385. SWITZERLAND BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 386. SWITZERLAND BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 387. SWITZERLAND BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 388. SWITZERLAND BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 389. SWITZERLAND BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 390. SWITZERLAND BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 391. SWITZERLAND BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 392. SWITZERLAND BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 393. TURKEY BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 394. TURKEY BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 395. TURKEY BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 396. TURKEY BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 397. TURKEY BIOBANKS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 398. TURKEY BIOBANKS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 399. TURKEY BIOBANKS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 400. TURKEY BIOBANKS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 401. TURKEY BIOBANKS MARKET SIZE, BY OWNERSHIP, 2018-2030 (USD MILLION)
• TABLE 402. UNITED ARAB EMIRATES BIOBANKS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 403. UNITED ARAB EMIRATES BIOBANKS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 404. UNITED ARAB EMIRATES BIOBANKS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 405. UNITED ARAB EMIRATES BIOBANKS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 406. UNITED ARAB

The Biobanks Market was valued at USD 115.43 billion in 2024 and is projected to grow to USD 130.56 billion in 2025, with a CAGR of 13.49%, reaching USD 246.72 billion by 2030.

Biobanks have emerged as vital repositories of biological samples and associated data, fueling breakthroughs across research, diagnostics, and personalized medicine. In today's rapidly evolving scientific environment, these facilities are at the core of innovations that support clinical and translational research. Over the past decade, advancements in technology coupled with an increasing understanding of genomic and molecular underpinnings have positioned biobanks as strategic assets. This evolution has stimulated improvements in storage, sample analysis, and data management, thereby enhancing the reliability and reproducibility of scientific findings. The expansive role of biobanks not only accelerates drug discovery but also contributes significantly to patient-specific therapies. Stakeholders from academia, biotechnology, and healthcare are increasingly collaborating to unlock new possibilities while addressing ethical, regulatory, and operational challenges. As the market shifts toward integrated digital platforms, robust infrastructure, and advanced analytical tools, the biobank landscape is poised for transformative growth. Recognizing both historical milestones and emerging trends, this introduction sets the stage for a detailed exploration of market dynamics, segmentation strategies, and strategic insights that support effective decision-making in an increasingly competitive arena.

Transformative Shifts in the Landscape: Emerging Trends and Disruptive Forces

The evolution of the biobank ecosystem is driven by transformative shifts that reframe traditional methodologies while opening doors to pioneering approaches. Technological advancements, such as real-time monitoring systems, automated sample processing, and data analytics, are redefining collection and management practices. Amid a digital revolution, platforms are becoming more interoperable and user-centric, ensuring that the flow of data from sample collection to analysis is both rapid and secure. Regulatory reforms and evolving ethical considerations are also reshaping the market, prompting institutions to adopt more transparent and rigorous operational frameworks. Concurrently, increased investments in genomic research and personalized healthcare initiatives further stimulate these shifts as academia, hospitals, and commercial ventures recalibrate their strategies to align with present and future demands. In addition, the global focus on developing infrastructure for biobanking has fostered collaborations between private and public sectors. This environment is marked by swift adaptation and strategic realignment, enabling market players to overcome legacy challenges and leverage newfound opportunities. The resulting transformation is not only raising industry standards, but it is also creating pathways for unprecedented growth and collaborative innovation in biobanking worldwide.

Key Segmentation Insights: Comprehensive Analysis Across Multiple Dimensions

The biobank market is characterized by a complex yet insightful segmentation that facilitates targeted strategies and investments. The structure of this market is firstly observed through the perspective of type, with studies focusing on disease-oriented models, genomic-based approaches, population-based collections, and the increasingly relevant virtual biobank platforms. Additionally, segmentation by component plays a crucial role, as the market is examined through consumables, equipment, and services; specifically, equipment segmentation delves into areas such as alarms and monitoring systems, incubators and centrifuges, along with temperature control systems. On the services side, key operational elements such as data management, sample analysis, storage and processing, and transpost are critically evaluated. Further granularity is achieved when considering sample type segmentation, where blood derivatives, cell lines, nucleic acid, and tissues each present distinct analytical and operational parameters. The application of biobanking is also segmented into clinical diagnostics, personalized medicine, research, and therapeutics, with the therapeutics domain further dissected into drug development and gene editing ventures. Market players also align their investment decisions based on end user segments such as academic institutions, biotechnology companies, hospitals, and pharmaceutical companies. Ownership further refines the landscape into academic, commercial, and government biobanks. This multi-dimensional segmentation offers a deep dive into the diverse needs and innovation trajectories that collectively drive the market forward.

Based on Type, market is studied across Disease-Oriented, Genomic-Based, Population-Based, and Virtual.

Based on Component, market is studied across Consumables, Equipment, and Services. The Equipment is further studied across Alarms & Monitoring Systems, Incubators & Centrifuges, and Temperature Control Systems. The Services is further studied across Data Management, Sample Analysis, Storage & Processing, and Transpost.

Based on Sample Type, market is studied across Blood Derivatives, Cell Lines, Nucleic Acid, and Tissues.

Based on Application, market is studied across Clinical Diagnostics, Personalized Medicine, Research, and Therapeutics. The Therapeutics is further studied across Drug Development and Gene Editing.

Based on End User, market is studied across Academic Institutions, Biotechnology Companies, Hospitals, and Pharmaceutical Companies.

Based on Ownership, market is studied across Academic Biobanks, Commercial Biobanks, and Government Biobanks.

Key Regional Insights: Global Diffusion and Local Nuances

Examining the biobank landscape on a global scale unravels significant regional trends and market drivers. In the Americas, a combination of advanced infrastructure, robust funding initiatives, and a well-established network of research institutions creates a fertile ground for biobanking innovation. Both government and private sectors contribute extensively to research support and infrastructure development across these regions, making it a hotspot for cutting-edge developments. In contrast, the Europe, Middle East, and Africa regions exhibit a unique blend of regulatory dynamics and a commitment to traditional as well as pioneering research methodologies. These regions place a strong emphasis on ethical standards and data transparency while steadily advancing their technological capabilities. Meanwhile, the Asia-Pacific market reflects rapid economic growth, a surge in biotechnological investments, and an expanding research framework that is quickly adapting to the demands of modern biobanking. The interplay of local policies, infrastructural investments, and growing public-private partnerships in these regions creates diverse opportunities and challenges, ultimately contributing to the global diffusion and evolution of biobank practices.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights: Market Leaders Shaping the Competitive Landscape

A number of prominent companies are making substantial contributions to driving growth and innovation within the biobank industry. Leading organizations like Acorn Biolabs, Inc. and AMS Biotechnology (Europe) Limited have carved out niches by providing advanced solutions tailored to specific market needs. Companies such as Artizan Biosciences, Inc. and ASKION GmbH have set exemplary high standards through their commitment to precision and technological advancement. Industry titans including Avantor, Inc. and Bay Biosciences LLC, alongside established brands such as Beckman Coulter, Inc. by Danaher Corporation and Becton, Dickinson and Company, are continuously enhancing operational efficiencies and pushing the boundaries of research solutions. Enterprises like BioIVT LLC, BioKryo by L'AIR LIQUIDE S.A., BioLife Solutions Inc., and BocaBio demonstrate notable strength by integrating innovative technologies into their service offerings. Furthermore, diversified multinational corporations such as Charles River Laboratories International, Inc., Cryoport Systems, LLC, CTIBiotech, and Cureline, Inc. further fortify market competitiveness. Other influential players, including Firalis Group, Greiner AG, Hamilton Company, LVL Technologies GmbH & Co. KG, Merck KGaA, Micronic Holding B.V., ProteoGenex, Inc., Provia Laboratories, LLC, Qiagen N.V., Shanghai Outdo Biotech Co. Ltd, Taylor-Wharton, Tecan Trading AG, Thermo Fisher Scientific Inc., and UK Biobank Limited, continue to drive innovative research and deploy forward-thinking solutions, each leaving a significant imprint on this rapidly maturing market.

The report delves into recent significant developments in the Biobanks Market, highlighting leading vendors and their innovative profiles. These include Acorn Biolabs, Inc., AMS Biotechnology (Europe) Limited, Artizan Biosciences, Inc., ASKION GmbH, Avantor, Inc., Bay Biosciences LLC, Beckman Coulter, Inc. by Danaher Corporation, Becton, Dickinson and Company, BioIVT LLC, BioKryo by L'AIR LIQUIDE S.A., BioLife Solutions Inc., BocaBio, Charles River Laboratories International, Inc., Cryoport Systems, LLC, CTIBiotech, Cureline, Inc., Firalis Group, Greiner AG, Hamilton Company, LVL Technologies GmbH & Co. KG, Merck KGaA, Micronic Holding B.V., ProteoGenex, Inc., Provia Laboratories, LLC, Qiagen N.V., Shanghai Outdo Biotech Co. Ltd, Taylor-Wharton, Tecan Trading AG, Thermo Fisher Scientific Inc., and UK Biobank Limited. Actionable Recommendations for Industry Leaders: Strategic Steps for Future Growth

Industry leaders are advised to adopt comprehensive strategies that address both current challenges and future opportunities in the rapidly evolving biobank market. A primary recommendation is to invest in state-of-the-art technological infrastructure that supports automated processes and real-time monitoring. Embracing digitalization not only enhances operational efficiency but also ensures data integrity and security across the supply chain. Leaders should also consider fostering partnerships with key stakeholders, including academic institutions, biotechnology firms, and healthcare providers, to facilitate knowledge exchange and joint ventures. Building resilient, compliant frameworks that align with stringent regulatory standards is essential; hence, legal and procedural audits should be conducted routinely to uphold transparency and accountability. It is imperative to tailor innovations based on market segmentation insights: customizing solutions to address the varied demands based on type, component, sample type, application, end user, and ownership segments. Furthermore, understanding regional dynamics and adapting to local market conditions will enable more informed decision-making, particularly in diverse territories such as the Americas, Europe, Middle East and Africa, and Asia-Pacific. These strategic recommendations are geared toward positioning companies to capture growth opportunities while mitigating risks in an environment characterized by relentless innovation and changing market paradigms.

Conclusion: Embracing Change and Navigating Future Opportunities

In conclusion, the analysis of the biobank market reveals a vibrant and evolving industry defined by technological innovation, strategic segmentation, and a global spread of opportunities. The comprehensive review provided throughout this document underscores that biobanks are no longer solely repositories for biological samples; they are dynamic entities central to advancements in personalized medicine, clinical diagnostics, and advanced research. With transformative shifts reshaping the market and key players driving technological and operational progress, stakeholders can leverage these insights to navigate the competitive landscape. As emerging trends continue to accelerate, the collective focus on integrating robust infrastructural investments, adhering to stringent regulatory standards, and fostering strategic collaborations will determine the success of industry participants. This evolving market offers both substantial challenges and compelling opportunities, making it imperative for organizations to remain agile and informed as they embark on new initiatives and expansion strategies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing demand for personalized medicine and genomics
    • 5.1.1.2. Rapid expansion of precision medicine initiatives
    • 5.1.1.3. Increasing investments in biobanking infrastructure development
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulatory compliances on the development and international reach of biobanking
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in technology enhancing efficiency of biobanking processes and data handling
    • 5.1.3.2. Leveraging big data analytics in biobanks to enhance personalized healthcare outcomes
  • 5.1.4. Challenges
    • 5.1.4.1. Data privacy and security issues in biobanks
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Rising preference for population-based biobanks for facilitating longitudinal studies on disease progression and prevention strategies
  • 5.2.2. Application: Expanding application of biobanks in clinical diagnostics for storing and accessing biological samples
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Biobanks Market, by Type

• 6.1. Introduction
• 6.2. Disease-Oriented
• 6.3. Genomic-Based
• 6.4. Population-Based
• 6.5. Virtual

7. Biobanks Market, by Component

• 7.1. Introduction
• 7.2. Consumables
• 7.3. Equipment
  • 7.3.1. Alarms & Monitoring Systems
  • 7.3.2. Incubators & Centrifuges
  • 7.3.3. Temperature Control Systems
• 7.4. Services
  • 7.4.1. Data Management
  • 7.4.2. Sample Analysis
  • 7.4.3. Storage & Processing
  • 7.4.4. Transpost

8. Biobanks Market, by Sample Type

• 8.1. Introduction
• 8.2. Blood Derivatives
• 8.3. Cell Lines
• 8.4. Nucleic Acid
• 8.5. Tissues

9. Biobanks Market, by Application

• 9.1. Introduction
• 9.2. Clinical Diagnostics
• 9.3. Personalized Medicine
• 9.4. Research
• 9.5. Therapeutics
  • 9.5.1. Drug Development
  • 9.5.2. Gene Editing

10. Biobanks Market, by End User

• 10.1. Introduction
• 10.2. Academic Institutions
• 10.3. Biotechnology Companies
• 10.4. Hospitals
• 10.5. Pharmaceutical Companies

11. Biobanks Market, by Ownership

• 11.1. Introduction
• 11.2. Academic Biobanks
• 11.3. Commercial Biobanks
• 11.4. Government Biobanks

12. Americas Biobanks Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Biobanks Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Biobanks Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. UK Biobank launches advanced proteomics study for disease research
  • 15.3.2. ICMR's new diabetes biobank in Chennai for diabetes research and management in India
  • 15.3.3. Strategic partnership between UK and Oxford Nanopore aims to advance genomics for enhanced healthcare and biosecurity
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Acorn Biolabs, Inc.
• 2. AMS Biotechnology (Europe) Limited
• 3. Artizan Biosciences, Inc.
• 4. ASKION GmbH
• 5. Avantor, Inc.
• 6. Bay Biosciences LLC
• 7. Beckman Coulter, Inc. by Danaher Corporation
• 8. Becton, Dickinson and Company
• 9. BioIVT LLC
• 10. BioKryo by L'AIR LIQUIDE S.A.
• 11. BioLife Solutions Inc.
• 12. BocaBio
• 13. Charles River Laboratories International, Inc.
• 14. Cryoport Systems, LLC
• 15. CTIBiotech
• 16. Cureline, Inc.
• 17. Firalis Group
• 18. Greiner AG
• 19. Hamilton Company
• 20. LVL Technologies GmbH & Co. KG
• 21. Merck KGaA
• 22. Micronic Holding B.V.
• 23. ProteoGenex, Inc.
• 24. Provia Laboratories, LLC
• 25. Qiagen N.V.
• 26. Shanghai Outdo Biotech Co. Ltd
• 27. Taylor-Wharton
• 28. Tecan Trading AG
• 29. Thermo Fisher Scientific Inc.
• 30. UK Biobank Limited